Literature DB >> 9167647

Hyponatremia and hypernatremia.

L F Fried1, P M Palevsky.   

Abstract

Hyponatremia and hypernatremia are common electrolyte disorders resulting from disorders in water homeostasis. Hyponatremia usually results from defects in free water excretion, although increased intake may also contribute. The treatment of hyponatremia has been controversial because of the high associated morbidity and mortality and the observation that rapid correction of hyponatremia is associated with the development of central pontine myelinolysis. Mild hyponatremia should be treated with water restriction alone, whereas severe acute or symptomatic hyponatremia should initially be corrected rapidly until symptoms resolve followed by more gradual correction. In all cases, treatment should be individualized on the basis of severity, cause, and duration of the hyponatremia. Hypernatremia results from impaired water ingestion, although increased water losses are often contributory. Hospital-acquired hypernatremia is usually iatrogenic because of inadequate water prescription and is therefore preventable. Hypernatremia is also associated with high morbidity and mortality, both as a result of the underlying disease and inadequate treatment. The primary treatment of hypernatremia is water replacement-repleting water deficits and replacing ongoing losses. Additional treatment should be directed at eliminating excess water losses.

Entities:  

Mesh:

Year:  1997        PMID: 9167647     DOI: 10.1016/s0025-7125(05)70535-6

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  26 in total

Review 1.  Hyponatremia.

Authors:  Jameela Al-Salman; David Kemp; Daniel Randall
Journal:  West J Med       Date:  2002-05

2.  Electrolytes in the aging.

Authors:  Lynn E Schlanger; James L Bailey; Jeff M Sands
Journal:  Adv Chronic Kidney Dis       Date:  2010-07       Impact factor: 3.620

Review 3.  Electroencephalography of encephalopathy in patients with endocrine and metabolic disorders.

Authors:  Roland Faigle; Raoul Sutter; Peter W Kaplan
Journal:  J Clin Neurophysiol       Date:  2013-10       Impact factor: 2.177

4.  Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects.

Authors:  Susan E Shoaf; Patricia Bricmont; Suresh Mallikaarjun
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

5.  Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects.

Authors:  Susan E Shoaf; Suresh Mallikaarjun; Patricia Bricmont
Journal:  Eur J Clin Pharmacol       Date:  2011-08-19       Impact factor: 2.953

6.  Hyponatremic dehydration: an analysis of 78 cases.

Authors:  H Caksen; D Odabaş; S Sar; V Celebi; S Arslan; M Kuru; M Abuhandan
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 7.  Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.

Authors:  Chaya G Bhuvaneswar; Ross J Baldessarini; Veronica L Harsh; Jonathan E Alpert
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

8.  Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice.

Authors:  Kathene Candace Johnson-Henry; David J Mitchell; Yaron Avitzur; Esther Galindo-Mata; Nicola L Jones; Philip M Sherman
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

9.  Conivaptan: Evidence supporting its therapeutic use in hyponatremia.

Authors:  Melissa Li-Ng; Joseph G Verbalis
Journal:  Core Evid       Date:  2010-06-15

Review 10.  Age-associated abnormalities of water homeostasis.

Authors:  Laura E Cowen; Steven P Hodak; Joseph G Verbalis
Journal:  Endocrinol Metab Clin North Am       Date:  2013-04-17       Impact factor: 4.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.